company background image
HIK logo

Hikma Pharmaceuticals LSE:HIK Stock Report

Last Price

UK£19.19

Market Cap

UK£4.3b

7D

2.4%

1Y

14.2%

Updated

28 Mar, 2024

Data

Company Financials +

Hikma Pharmaceuticals PLC

LSE:HIK Stock Report

Market Cap: UK£4.3b

HIK Stock Overview

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance1/6
Financial Health4/6
Dividends5/6

Hikma Pharmaceuticals PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hikma Pharmaceuticals
Historical stock prices
Current Share PriceUK£19.19
52 Week HighUK£22.22
52 Week LowUK£16.46
Beta0.45
1 Month Change-3.62%
3 Month Change7.24%
1 Year Change14.16%
3 Year Change-17.27%
5 Year Change7.75%
Change since IPO580.32%

Recent News & Updates

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Recent updates

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Dec 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Dec 12
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Sep 19
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Sep 01
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Jun 21
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Jun 02
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Mar 14
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Feb 21
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease

Feb 22
I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?

Feb 03
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?

Are Hikma Pharmaceuticals's (LON:HIK) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 20
Are Hikma Pharmaceuticals's (LON:HIK) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Shareholder Returns

HIKGB PharmaceuticalsGB Market
7D2.4%2.3%0.9%
1Y14.2%2.2%2.2%

Return vs Industry: HIK exceeded the UK Pharmaceuticals industry which returned 2.5% over the past year.

Return vs Market: HIK exceeded the UK Market which returned 2.7% over the past year.

Price Volatility

Is HIK's price volatile compared to industry and market?
HIK volatility
HIK Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.1%
10% least volatile stocks in GB Market2.6%

Stable Share Price: HIK has not had significant price volatility in the past 3 months.

Volatility Over Time: HIK's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19789,100Riad Mishlawihttps://www.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Hikma Pharmaceuticals PLC Fundamentals Summary

How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap?
HIK fundamental statistics
Market capUK£4.26b
Earnings (TTM)UK£150.54m
Revenue (TTM)UK£2.28b

28.3x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HIK income statement (TTM)
RevenueUS$2.88b
Cost of RevenueUS$1.47b
Gross ProfitUS$1.41b
Other ExpensesUS$1.22b
EarningsUS$190.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 08, 2024

Earnings per share (EPS)0.86
Gross Margin48.94%
Net Profit Margin6.61%
Debt/Equity Ratio50.9%

How did HIK perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

84%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.